reports
- Geir Hiller Holom
Oncoinvent (Buy, TP: NOK2.70) - Recruitment is key
Oncoinvent announced completed inclusion of the initial safety lead-in in the RAD-18-003 trial. However, (as planned) it was based on just six patients. Management said it expects the pace of recruitment to pick up sharply following completion of the safety lead-in, the trial proceeding to the randomised part and more sites being opened. We also believe recruitment will accelerate, albeit far slower than the guidance, and that the pace to date has increased investor uncertainty. We have therefor...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.